Revance to Participate in the Credit Suisse Healthcare Conference
November 07 2018 - 4:05PM
Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing next-generation neuromodulators for use in
treating aesthetic and therapeutic conditions, today announced that
the Company will participate in the Credit Suisse Healthcare
Conference in Phoenix, AZ.
President and Chief Executive Officer, Dan Browne, is scheduled
to present on Wednesday, November 14 at 3:25pm MT (5:25pm ET).
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company's
website at www.revance.com. The webcast replay will be available
after the conclusion of the live presentation for approximately 30
days.
About Revance Therapeutics, Inc.
Revance Therapeutics is an emerging Silicon Valley biotechnology
leader developing neuromodulators for the treatment of aesthetic
and therapeutic conditions. Revance uses a unique proprietary,
stabilizing excipient peptide technology to create novel,
differentiated therapies. The company’s lead compound,
DaxibotulinumtoxinA for Injection (RT002), is in clinical
development for a broad range of aesthetic and therapeutic
indications, including glabellar lines, cervical dystonia, plantar
fasciitis, upper limb spasticity and chronic migraine. RT002 has
the potential to be the first long-acting neuromodulator. The
company is advancing a robust pipeline of injectable and topical
formulations of DaxibotulinumtoxinA. More information on Revance
may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181107005144/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.:Ami
Bavishi, 212-213-0006abavishi@burnsmc.comorMEDIAGeneral
Media:TOGORUN:Mariann Caprino, 917-242-1087m.caprino@togorun.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024